Form 8-K - Current report:
SEC Accession No. 0001641172-25-017873
Filing Date
2025-07-03
Accepted
2025-07-03 17:25:45
Documents
16
Period of Report
2025-07-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 47674
2 EX-1.1 ex1-1.htm EX-1.1 269472
3 EX-5.1 ex5-1.htm EX-5.1 15827
4 GRAPHIC ex5-1_001.jpg GRAPHIC 6140
  Complete submission text file 0001641172-25-017873.txt   621189

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tvgn-20250703.xsd EX-101.SCH 3814
6 XBRL DEFINITION FILE tvgn-20250703_def.xml EX-101.DEF 26690
7 XBRL LABEL FILE tvgn-20250703_lab.xml EX-101.LAB 36843
8 XBRL PRESENTATION FILE tvgn-20250703_pre.xml EX-101.PRE 25314
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5977
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41002 | Film No.: 251106437
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)